<table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="tbl4" position="float"><object-id pub-id-type="doi">10.7554/eLife.18082.009</object-id><label>Table 4.</label><caption><p>Antibiogram of <italic>E. coli</italic> causing bacteraemia in Northeast Thailand.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.18082.009">http://dx.doi.org/10.7554/eLife.18082.009</ext-link></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top">Antibiotic category</th><th valign="top">Antibiotic agents</th><th valign="top">CAB <break/>(n&#160;= 3382 patients)</th><th valign="top">HCAB <break/>(n&#160;= 494 patients)</th><th valign="top">HAB <break/>(n&#160;= 403 patients)</th><th valign="top">p values</th></tr></thead><tbody><tr><td rowspan="4" valign="top">Aminoglycosides</td><td valign="top">Gentamicin</td><td valign="top">559/3346 (17%)</td><td valign="top">166/484 (34%)</td><td valign="top">178/398 (45%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Tobramycin</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Amikacin</td><td valign="top">72/2685 (3%)</td><td valign="top">26/397 (7%)</td><td valign="top">32/326 (10%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Netilmicin</td><td valign="top">68/1394 (5%)</td><td valign="top">25/259 (10%)</td><td valign="top">42/254 (17%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Anti-MRSA cephalosporins</td><td valign="top">Ceftaroline</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td rowspan="2" valign="top">Antipseudomonal penicillins + &#946; lactamase inhibitors</td><td valign="top">Ticarcillin-clauvanic acid</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Piperacillin-tazobactam</td><td valign="top">23/511 (5%)</td><td valign="top">10/103 (10%)</td><td valign="top">15/89 (17%)</td><td valign="top">&lt;0.001</td></tr><tr><td rowspan="3" valign="top">Carbapenems</td><td valign="top">Ertapenem</td><td valign="top">4/1325 (&lt;1%)</td><td valign="top">1/235 (&lt;1%)</td><td valign="top">4/205 (2%)</td><td valign="top">0.02</td></tr><tr><td valign="top">Imipenem</td><td valign="top">3/2449 (&lt;1%)</td><td valign="top">0/386 (0%)</td><td valign="top">3/344 (1%)</td><td valign="top">0.04</td></tr><tr><td valign="top">Meropenem</td><td valign="top">0/1988 (0%)</td><td valign="top">1/314 (&lt;1%)</td><td valign="top">1/244 (&lt;1%)</td><td valign="top">0.05</td></tr><tr><td rowspan="2" valign="top">Non-extended spectrum cephalosporins</td><td valign="top">Cefazolin</td><td valign="top">468/1095 (43%)</td><td valign="top">115/174 (66%)</td><td valign="top">80/102 (78%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Cefuroxime</td><td valign="top">219/1438 (15%)</td><td valign="top">96/226 (42%)</td><td valign="top">102/202 (50%)</td><td valign="top">&lt;0.001</td></tr><tr><td rowspan="3" valign="top">Extended-spectrum cephalosporins</td><td valign="top">Cefotaxime</td><td valign="top">501/3076 (16%)</td><td valign="top">199/455 (44%)</td><td valign="top">185/361 (51%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Ceftazidime</td><td valign="top">392/3020 (13%)</td><td valign="top">165/446 (37%)</td><td valign="top">164/351 (47%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Cefepime</td><td valign="top">30/293 (10%)</td><td valign="top">12/42 (29%)</td><td valign="top">18/53 (34%)</td><td valign="top">&lt;0.001</td></tr><tr><td rowspan="2" valign="top">Cephamycins</td><td valign="top">Cefoxitin</td><td valign="top">36/1200 (3%)</td><td valign="top">16/215 (7%)</td><td valign="top">16/195 (8%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Cefotetan</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Fluoroquinolones</td><td valign="top">Ciprofloxacin</td><td valign="top">728/3000 (24%)</td><td valign="top">221/452 (49%)</td><td valign="top">171/384 (45%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Folate pathway inhibitors</td><td valign="top">Trimethoprim-sulphamethoxazole</td><td valign="top">1738/3007 (58%)</td><td valign="top">294/442 (67%)</td><td valign="top">225/350 (64%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Glycylcyclines</td><td valign="top">Tigecycline</td><td valign="top">0/7 (0%)</td><td valign="top">NA</td><td valign="top">0/1 (0%)</td><td valign="top">-</td></tr><tr><td valign="top">Monobactams</td><td valign="top">Aztreonam</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Penicillins</td><td valign="top">Ampicillin</td><td valign="top">2246/2843 (79%)</td><td valign="top">371/420 (88%)</td><td valign="top">301/342 (88%)</td><td valign="top">&lt;0.001</td></tr><tr><td rowspan="2" valign="top">Penicillins + &#946; lactamase inhibitors</td><td valign="top">Amoxicillin-clavulanic acid</td><td valign="top">790/3074 (26%)</td><td valign="top">191/463 (41%)</td><td valign="top">158/373 (42%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Ampicillin-sulbactam</td><td valign="top">83/296 (28%)</td><td valign="top">18/48 (38%)</td><td valign="top">12/25 (48%)</td><td valign="top">0.06</td></tr><tr><td valign="top">Phenicols</td><td valign="top">Chloramphenicol</td><td valign="top">14/63 (22%)</td><td valign="top">1/4 (25%)</td><td valign="top">3/5 (60%)</td><td valign="top">0.14</td></tr><tr><td valign="top">Phosphonic acids</td><td valign="top">Fosfomycin</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Polymyxins</td><td valign="top">Colistin*</td><td valign="top">2/34 (6%)</td><td valign="top">0/6 (0%)</td><td valign="top">1/6 (17%)</td><td valign="top">0.61</td></tr><tr><td valign="top">MDR</td><td valign="top"/><td valign="top">1177/3382 (35%)</td><td valign="top">288/494 (58%)</td><td valign="top">252/403 (63%)</td><td valign="top">&lt;0.001</td></tr></tbody></table><table-wrap-foot><fn id="tblfn7"><p>NOTE: Data are number of isolates demonstrating non-susceptible to the antimicrobial over the total number of isolates tested (%). CAB&#160;=&#160;Community-acquired bacteraemia, HCAB&#160;=&#160;Healthcare-associated bacteraemia, HAB&#160;= Hospital-acquired bacteraemia, and NA&#160;=&#160;Not available. The first isolate of each patient was used. MDR: non-susceptible to &#8805;1 agent in &#8805;3 antimicrobial categories.</p></fn><fn id="tblfn8"><p>*Defined by using an inhibition zone of &lt;11 mm.</p></fn></table-wrap-foot></table-wrap>